152 related articles for article (PubMed ID: 36171843)
1. Adverse Endocrine-Related Effects of Pembrolizumab Precipitating Severe Hyponatremia.
Baldawi MB; Dhami B; Gosai J; Al-Khafaji RH
Cureus; 2022 Aug; 14(8):e28393. PubMed ID: 36171843
[TBL] [Abstract][Full Text] [Related]
2. Simultaneous Presentation of Secondary Adrenal Insufficiency and Primary Hypothyroidism due to Pembrolizumab: A Case Report.
Khatri S; Alom M; Kashfi S; Atallah J; Goswami G
J Investig Med High Impact Case Rep; 2023; 11():23247096231194401. PubMed ID: 37642143
[TBL] [Abstract][Full Text] [Related]
3. Polyendocrinopathy Resulting From Pembrolizumab in a Patient With a Malignant Melanoma.
Paepegaey AC; Lheure C; Ratour C; Lethielleux G; Clerc J; Bertherat J; Kramkimel N; Groussin L
J Endocr Soc; 2017 Jun; 1(6):646-649. PubMed ID: 29264517
[TBL] [Abstract][Full Text] [Related]
4. Behcet's-like syndrome following pembrolizumab: An immune-related adverse event associated with programmed death receptor-1 inhibitor therapy.
Thomas S; Bae C; Joy-Ann T; Traverse W
J Oncol Pharm Pract; 2020 Jun; 26(4):995-999. PubMed ID: 31575354
[TBL] [Abstract][Full Text] [Related]
5. [Pituitary immune-related adverse events induced by programmed cell death protein 1 inhibitors in advanced lung cancer patients: A report of 3 cases].
Gu YC; Liu Y; Xie C; Cao BS
Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Apr; 54(2):369-375. PubMed ID: 35435206
[TBL] [Abstract][Full Text] [Related]
6. Isolated Adrenocorticotropic Hormone Deficiency Associated with Severe Hyperkalemia During Pembrolizumab Therapy in a Patient with Ureteral Cancer and an Ileal Conduit: A Case Report and Literature Review.
Hinata Y; Ohara N; Sakurai Y; Koda R; Yoneoka Y; Takada T; Hara N; Nishiyama T
Am J Case Rep; 2021 Jul; 22():e931639. PubMed ID: 34262010
[TBL] [Abstract][Full Text] [Related]
7. Multiple autoimmune side effects of immune checkpoint inhibitors in a patient with metastatic melanoma receiving pembrolizumab.
Kethireddy N; Thomas S; Bindal P; Shukla P; Hegde U
J Oncol Pharm Pract; 2021 Jan; 27(1):207-211. PubMed ID: 32390537
[TBL] [Abstract][Full Text] [Related]
8. Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis.
Barroso-Sousa R; Barry WT; Garrido-Castro AC; Hodi FS; Min L; Krop IE; Tolaney SM
JAMA Oncol; 2018 Feb; 4(2):173-182. PubMed ID: 28973656
[TBL] [Abstract][Full Text] [Related]
9. Case report: reinitiating pembrolizumab treatment after small bowel perforation.
Beck TN; Kudinov AE; Dulaimi E; Boumber Y
BMC Cancer; 2019 Apr; 19(1):379. PubMed ID: 31018834
[TBL] [Abstract][Full Text] [Related]
10. Challenges and pitfalls in the management of endocrine toxicities from immune checkpoint inhibitors: a case presentation of synchronous thyrotoxicosis and primary adrenal insufficiency in a melanoma patient.
Spagnolo CC; Campo I; Campennì A; Cardile D; Cannavò S; Silvestris N; Santarpia M; Ruggeri RM
Hormones (Athens); 2024 Feb; ():. PubMed ID: 38421588
[TBL] [Abstract][Full Text] [Related]
11. Pembrolizumab in the management of metastatic melanoma.
Spain L; Younger E; Hatipoglu E; Larkin J
Melanoma Manag; 2015 Nov; 2(4):315-325. PubMed ID: 30190860
[TBL] [Abstract][Full Text] [Related]
12. Pembrolizumab-induced hypothyroidism caused reversible increased serum creatinine levels: a case report.
Matsuoka N; Tsuji K; Ichihara E; Hara T; Fukushima K; Toma K; Kitamura S; Inagaki K; Sugiyama H; Wada J
BMC Nephrol; 2020 Mar; 21(1):113. PubMed ID: 32234009
[TBL] [Abstract][Full Text] [Related]
13. Progression of Hypopituitarism and Hypothyroidism after Treatment with Pembrolizumab in a Patient with Adrenal Metastasis from Non-small-cell Lung Cancer.
Yamagata S; Kageyama K; Takayasu S; Asari Y; Makita K; Terui K; Daimon M
Intern Med; 2019 Dec; 58(24):3557-3562. PubMed ID: 31462588
[TBL] [Abstract][Full Text] [Related]
14. Non-bacterial cystitis secondary to pembrolizumab: A case report and review of the literature.
He X; Tu R; Zeng S; He Z; Liu S; Fang Y
Curr Probl Cancer; 2022 Aug; 46(4):100863. PubMed ID: 35687965
[TBL] [Abstract][Full Text] [Related]
15. Acute Kidney Injury after Pembrolizumab-Induced Adrenalitis and Adrenal Insufficiency.
Hanna RM; Selamet U; Bui P; Sun SF; Shenouda O; Nobakht N; Barsoum M; Arman F; Rastogi A
Case Rep Nephrol Dial; 2018; 8(2):171-177. PubMed ID: 30197906
[TBL] [Abstract][Full Text] [Related]
16. Immune checkpoint inhibitors and adrenal insufficiency: a large-sample case series study.
Cui K; Wang Z; Zhang Q; Zhang X
Ann Transl Med; 2022 Mar; 10(5):251. PubMed ID: 35402601
[TBL] [Abstract][Full Text] [Related]
17. Safety of pembrolizumab for the treatment of melanoma.
Martin-Liberal J; Kordbacheh T; Larkin J
Expert Opin Drug Saf; 2015 Jun; 14(6):957-64. PubMed ID: 25927979
[TBL] [Abstract][Full Text] [Related]
18. Association of Anti-Programmed Cell Death 1 Antibody Treatment With Risk of Recurrence of Toxic Effects After Immune-Related Adverse Events of Ipilimumab in Patients With Metastatic Melanoma.
Brunot A; Grob JJ; Jeudy G; Grange F; Guillot B; Kramkimel N; Mortier L; Le Corre Y; Aubin FF; Mansard S; Lebbé C; Blom A; Montaudie H; Giacchero D; Prey S; Legoupil D; Guyot A; Amini-Adle M; Granel-Brocard F; Meyer N; Dinulescu M; Edeline J; Campillo-Gimenez B; Lesimple T
JAMA Dermatol; 2020 Sep; 156(9):982-986. PubMed ID: 32667663
[TBL] [Abstract][Full Text] [Related]
19. Management of Adverse Events Following Treatment With Anti-Programmed Death-1 Agents.
Weber JS; Postow M; Lao CD; Schadendorf D
Oncologist; 2016 Oct; 21(10):1230-1240. PubMed ID: 27401894
[TBL] [Abstract][Full Text] [Related]
20. Severe arthritis and tenosynovitis caused by immune checkpoint blockade therapy with pembrolizumab (anti-PD-1 antibody).
Jagpal A; Choudhary G; Chokr J
Proc (Bayl Univ Med Cent); 2019 Jul; 32(3):419-421. PubMed ID: 31384207
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
